An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin.
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2016
At a glance
- Drugs Pasireotide (Primary)
- Indications Gastrointestinal cancer; Nelson's syndrome; Neuroendocrine tumours; Pancreatic cancer; Pituitary tumours
- Focus Biomarker; Therapeutic Use
- Sponsors Novartis
- 15 Jun 2016 Status changed from completed to discontinued.
- 17 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 May 2014 Planned End Date changed from 1 Jan 2014 to 1 Apr 2015, as per ClinicalTrials.gov record.